An Integrative Approach for management of Mucormycosis along with Ayurveda.


  • Dr. Gopesh Mangal Executive Editor, International Journal of Ayurveda and Traditional Medicine
  • Dr. Pushpa Raj Poudel Executive Officer, Provincial HEOC, Butwal, Lumbini Province, Nepal.


COVID-19, Ayurveda, Mucormycosis, Integrative Approach


Across the globe and mainly in India, several cases of mucormycosis in people with COVID-19 have been increasingly reported. The rise in the number of cases, the emergence of new risk factors and causative agents, mortality associated with mucormycosis in India is considerably high and the challenges in managing the disease.

Mucormycosis (Zygomycosis, phycomycosis) is an acute opportunistic infection caused by a saprophytic fungus that belongs to the class of Phycomycetes. Rhizopus arrhizus is the most common etiological agent of mucormycosis in India, and globally but other variants are also found as Rhizopus microsporus, Rhizopus homothallicus, and Apophysomyces.

The primary reason found for mucormycosis in people with COVID-19 is  an ideal environment of low oxygen (hypoxia), high glucose (diabetes, new-onset hyperglycemia, steroid-induced hyperglycemia), acidic medium (metabolic acidosis, diabetic ketoacidosis, high iron levels (increased ferritins) and decreased phagocytic activity of white blood cells (WBC) due to immunosuppression. Immunosuppression is due to SARS-CoV-2 mediated, or steroid-mediated or other comorbidities present in the body. Several other risk factors including prolonged hospitalization with or without mechanical ventilators is another cause for immunosuppression.1

Symptoms of mucormycosis include pain and redness around the eyes and nose, fever, headache, cough, vomit with presence of blood in it, black and bloody nasal discharge, pain over one side of the face and in the sinuses, blackish discoloration over the nose, toothache, and painful and blurred vision, double vision, protrusion of the eyeball. The majority of mucormycosis infections have been seen in covid patients with diabetes or those with underlying and undetected high blood sugar.2

Although mucormycosis is a rare disease and it is associated with high morbidity and mortality ;it is being detected relatively frequently among Covid-19 patients after the second wave of the covid pandemic.  It  has become rampant throughout India and killed more than half of those infected. Patients most vulnerable to mucormycosis are those who have been treated with steroids and other drugs for Covid 19 to reduce inflammation. Diabetes is the major risk factor for fungal infection, along with other types of immunosuppressive conditions and also overuse of steroids.

Uncontrolled diabetes mellitus can alter the normal immunologic response of patients to infections. Such patients have decreased granulocyte phagocytic ability with altered polymorphonuclear leukocyte response. Reports have suggested that the ability of serum of immunocompromised patients to inhibit Rhizopus invitro is reduced, which makes them suitable hosts to opportunistic fungal infections.3,4

The treatment of mucormycosis involves the early initiation of therapy, the surgical debridement of infected tissue, antifungal therapy, and managing the underlying disease. Amphotericin B (AmB) is the first-line drug of choice; subsequently, posaconazole and isavuconazole are prescribed. The major drawbacks in managing mucormycosis in India are a gap in treatment protocol and the financial constraints of patients that they cannot afford liposomal AmB. 5 In the absence of surgical removal of the infected focus, antifungal therapy alone is rarely curative. Even when surgical debridement is combined with high-dose antifungal therapy, the mortality associated with mucormycosis is >50%. The unacceptably high mortality rate, limited options for therapy, and the extreme morbidity of highly disfiguring surgical therapy provide a clear mandate to understand the molecular mechanisms that govern pathogenesis with the hopes of developing alternative strategies to treat and prevent mucormycosis.6

In this context of prevention and effective management of mucormycosis; Ayurveda has got significant methods. The recommended Ayurvedic management protocol consists of personal hygiene, preventive medications, rasayana drugs, and antifungal medications. The protocol can be effectively managed with an integrative approach or standalone as per the clinical analysis of severity.

Personal hygiene

Oral hygiene: This  include procedures like Danta-dhavana (brushing the tooth), Pratisarana (Massaging the teeth and gums), Jivha nirlekhana (tongue cleaning), Gandoosha and Kavala (gargling), etc can act as a special care on common route of spread of mucormycosis ; nose,  oral cavity, and eyes. Neem (margosa or Azadirachta    indica),    fresh    stems    of Yastimadhu (Glycyrrhiza  glabra), Arjuna (Terminalia  arjuna), Vata (Ficus   bengalensis), Vijaysara (Pterocarpus   marsupium), Arka (Calotropis    gigantia), Khadira (Acacia    catechu), etc can be used for  Danta-dhavana (brushing  the  tooth). Pratisarana (Massaging the teeth and gums) is done with paste or powder of herbs or by honey/oil along with herbal powder. The commonly  used drugs for Pratisarana are Triphala,  Trikatu and Trijata mixed with honey. Recent researches have proved gum massage is good for dental and oral hygiene. These medicinal plants  have a role in the maintenance of oral health and are proven as a  potent antibacterial, antifungal, antiviral, and antioxidant in their properties.

Kavala and Gandoosha (Oil pulling):

Kavala and Gandoosha (Oil pulling)consists of  medicated oil and fluid wic are proven to protect the oral cavity from infection and inflammation by their antioxidant properties. Research has shown that oral mucosa does not act as a  semi-permeable membrane to allow toxins to pass through.7

Pratimarsha Nasya
Pratimarsha Nasya is indicated as a daily regimen to maintain the health of nasal passage Commonly oils are advised for Nasya which have antimicrobial activity and prevent the entry of infections in the respiratory tract and have a potent role. Anjana is indicated as a daily regimen to maintain the health of the eyes by applying medicated collyrium to the inner part of the eyelid. 

Dhoopana Karma
Dhoopana Karma- The drugs advised for the dhoopan karma possess antimicrobial and antifungal activity.  Commonly   used   as drugs are  Guggulu, Neem, Haridra, Kustha, Jatamansi, Sarjarasa,  Karanja, Vacha, etc  . Aparajita Dhuma Churna showed that flora before fumigation were rich in coliforms and many saprophytic fungi and after fumigation, the data showed a  considerable reduction in microbes.  It has significantly higher inhabitation of various Aspergillus species ;overall activity was more pronounced against bacteria as compared to fungi.8

Rasayana drugs
Administration of Rasayana (Immunomodulators) drugs like Amalaki, Guduchi, Vasa, Pippali, Ashwagandha, Haridra, etc. is beneficial to prevent the associated complications.

Common preparations which act as  respiratory immunomodulators are Chyavanprasha avleha   Agastya Haritaki Rasayana. Naimittika Rasayana like Shilajatu correct the hyperglycaemic episodes and produce their effect by enhancing the Agni and Ojas status in the patients, thereby improving metabolic and immune status.

If primarily disease is present in the Nasal route then the  Panchakarma procedures Nasya and Dhoom have beneficial effects. In the case of eye involvement,  Ashchotan /eye drops can be advised.

Diabetic Patient Management
If the patient is diabetic then  fair control  of Diabetes is one of the important concern and can be effectively managed by various herbs and herbo- mineral preparations as Trivanga Bhasma, Shiva gutika, Shilajeet , Triphala Churna, Nimbapatra, Haritaki(Terminalia chebula), kahadir( Acacia arabica), Mangifera indica, Eugenia jambolana, Allium cepa, Allium sativum, Aloe vera, Tinospora cordifolia, mentioned in Ayurvedic texts.

Antifungal Management
Krimihara Chikitsa is useful to prevent and manage microbes and fungi in Ayurveda. Rakta shodhaka, Raktaprasadaka drugs, and drugs for Pranvaha srotas /Urdhajatrujata roga   may have a significant role in Mucormycosis.   The drugs like Panchanimba Churna, Amrita Bhallataka / Rasamanikya/ Talasindhura / Talakeshwara  Rasa /Mallasindhura / Gandhaka Rasayana, Mahalaxmi Vilasa Rasa can be   recommended orally  according  to  the patients Dosha , Bala, and other parameters. Gandhaka  Rasayana solution in  higher concentration showed similar antifungal activity compared to Fluconazole against Candida albicans and Cryptococcus neoformans. It was more significant against Trycophytum rubrum and Aspergillus Niger than Fluconazole.9 Medicinal plants having antifungal properties like Allium sativum, Zingiber officinalis, Glycyrrhiza Glabra, Curcuma longa, Mentha piperita, Azadirachta indica Withania somnifera, Acorus calamus, Piper betel, Adhatoda vasica, Solanum xanthocarpum, Aloe Vera, and Ocimum sanctum have antifungal activity.10 Methanolic extracts of Solanum xanthocarpum and Datura metel inhibited the growth of Aspergillus fumigatus, A. flavus, and A. niger . Datura metel showed significant activity against Aspergillus. Similarly, Solanum xanthocarpum exhibited similar activity.11

Personal hygiene, preventive medications, Rasayana drugs, and Krimighna medications are preventive and curative aspects from Ayurveda. A rigid protocol along with Ayurveda is a special integrative approach for the effective management of Mucormycosis. Further observational evidence based studies and clinical trials are recommended to evaluate the effectiveness of Ayurvedic  medicine and therapy against Mucormycosis. 

Author Biographies

Dr. Gopesh Mangal, Executive Editor, International Journal of Ayurveda and Traditional Medicine

Executive Editor, International Journal of Ayurveda and Traditional Medicine

Dr. Pushpa Raj Poudel, Executive Officer, Provincial HEOC, Butwal, Lumbini Province, Nepal.

Provincial HEOC, Butwal, Lumbini Province, Nepal.




How to Cite

Mangal G, Poudel PR. An Integrative Approach for management of Mucormycosis along with Ayurveda. IJATM [Internet]. 2021 Jun. 30 [cited 2024 Feb. 21];3(4):8-10. Available from:




Most read articles by the same author(s)